Table-1.
Clinical profile and liver function characteristics of patients on admission.
| GRADE OF COVID-19 | LIVER FUNCTION | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| All | Asymptomatic | Mild | Moderate | Severe | p- value | Abnormal | Normal | p-value | |
| AGE (median ± S.D)) | 44 (15–82) | 41 ± 5.67 | 41.35 ± 18.38 | 49.42 ± 10.41 | 49.46 ± 17.96 | 0.186 | 45 (15–82) | 42 (20–77) | 0.411 |
| SEX (n, %) | |||||||||
| MALE | 61 (67%) | 2 (3.3%) | 35 (57.3%) | 9 (14.7%) | 15 (24.5%) | 0.508 | 47 (77%) | 14 (23%) | 1.00 |
| FEMALE | 30 (23%) | 2 (6.7%) | 14 (46.6%) | 3 (10%) | 11 (36.6%) | 23 (76.6%) | 7 (23.4%) | ||
| FEVER (n, %) | 56 (61.5%) | – | 34 (60.7%) | 8 (14.3%) | 14 (25%) | 0.037 | 43 (76.7%) | 13 (23.3%) | 0.969 |
| MYALGIA (n, %) | 36 (39.5%) | – | 24 (66.7%) | 6 (16.7%) | 6 (16.7%) | 0.047 | 24 (66.6%) | 12 (33.3%) | 0.061 |
| MALAISE (n, %) | 23 (25.2%) | – | 15 (65.2%) | 5 (21.7%) | 3 (13%) | 0.094 | 17 (73.9%) | 6 (26.1%) | 0.696 |
| HEADACHE (n, %) | 10 (10.9%) | – | 10 (100%) | 0 | 0 | 0.022 | 5 (50%) | 5 (50%) | 0.109 |
| COUGH (n, %) | 24 (26.3%) | – | 11 (45.8%) | 6 (25%) | 7 (29.2%) | 0.153 | 19 (79.1%) | 5 (20.9%) | 0.764 |
| ANOSMIA (n, %) | 5 (5.5%) | – | 5 (100%) | 0 | 0 | 0.209 | 3 (60%) | 2 (40%) | 0.361 |
| DIARRHEA (n, %) | 4 (4.4%) | 0 | 1 (25%) | 3 (75%) | 3 (75%) | 1 (25%) | 0.927 | ||
| PAIN ABDOMEN (n, %) | 1 (1.09%) | 1 (100%) | 0 | 0 | 0.833 | 1 (100%) | 0 | 0.587 | |
| ANOREXIA (n, %) | 3 (3.2%) | 2 (66.7%) | 0 | 1 (33.3%) | 0.881 | 3 (100%) | 0 | 0.083 | |
| BREATHLESSNESS (n, %) | 17 (18.6%) | 0 | 1 (5.9%) | 16 (94.1%) | <0.001 | 15 (88.2%) | 2 (11.8%) | 0.154 | |
| CHEST PAIN (n, %) | 3 (3.2%) | 0 | 1 (33.3%) | 2 (66.7% (66.6%) | 0.227 | 3 (100%) | 0 | 0.083 | |
| AST (n, %) | |||||||||
| <1 ULN | 38 (41.7) | 2 (5.3) | 27 (71.1) | 5 (13.2) | 4 (10.5) | <0.001 | |||
| 1-2 ULN | 33 (36.3) | 2 (6.1) | 19 (57.6) | 4 (12.1) | 8 (24.2) | ||||
| >2 ULN | 20 (22) | 0 | 3 (15) | 3 (15) | 14 (70) | ||||
| ALT (n, %) | |||||||||
| <1 ULN | 39 (42.9) | 2 (5.1) | 26 (66.7) | 5 (12.8) | 6 (15.4) | 0.004 | |||
| 1-2 ULN | 34 (37.3) | 2 (5.9) | 20 (58.8) | 4 (11.8) | 8 (23.5) | ||||
| >2 ULN | 18 (19.8) | 0 | 3 (16.7) | 3 (16.7) | 12 (66.7) | ||||
| ALP (n, %) | |||||||||
| <1 ULN | 72 (79.1) | 4 (5.6) | 46 (63.9) | 9 (12.5) | 13 (18.1) | <0.001 | |||
| 1-2 ULN | 12 (13.2) | 0 | 1 (8.3) | 1 (8.3) | 10 (83.3) | ||||
| >2 ULN | 7 (7.7) | 0 | 2 (28.6) | 2 (28.6) | 3 (42.9) | ||||
| T BIL (n, %) | |||||||||
| <1 ULN | 83 (91.2) | 4 (4.8) | 47 (56.6) | 11 (13.3) | 21 (25.3) | 0.301 | |||
| 1-2 ULN | 6 (6.6) | 0 | 2 (33.3) | 1 (16.7) | 3 (50) | ||||
| >2 ULN | 2 (2.2) | 0 | 0 | 0 | 2 (100) | ||||
| Data were expressed as median ± SD or as percentages. P values were calculated from independent samples t tests or x2 tests for categorical data. Bold data indicated p < 0.05. ALT- Alanine transaminase, AST – Aspartate transaminase, T BIL – total bilirubin, ULN – Upper limit of normal, COVID- coronavirus disease. | |||||||||